Drug-resistant tuberculosis: collaborative regional leadership required

Majumdar, Suman S; Marais, Ben J; Denholm, Justin T; Britton, Warwick J

doi:10.5694/mja13.00239

Topics

The drug-resistant tuberculosis crisis provides urgency and focus for coordinated action to improve regional health and development

1 Centre for International Health, Burnet Institute, Melbourne, VIC.
2 Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney, Sydney, NSW.
3 Discipline of Paediatrics and Child Health, University of Sydney, The Children's Hospital at Westmead, Sydney, NSW.
4 Victorian Infectious Diseases Service, Royal Melbourne Hospital, Peter Doherty Institute, Melbourne, VIC.
5 Department of Microbiology and Immunology, University of Melbourne, Melbourne, VIC.
6 National Health and Medical Research Council Centre of Research Excellence in Tuberculosis Control, Centenary Institute and University of Sydney, Sydney, NSW.

Correspondence: suman.majumdar@burnet.edu.au

Acknowledgements:

The opinions expressed are our own. They have, however, arisen and been refined from discussions within the newly formed Australasian Tuberculosis Forum, a coalition of organisations and individuals working in TB research, care and prevention. A full list of supporting organisations can be found at http://www.tbcre.org.au/australian-tb-forum.

Competing interests:

No relevant disclosures.

1. Abubakar I, Zignol M, Falzon D, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 2013; 13: 529-539.
2. World Health Organization. Global tuberculosis report 2013. Geneva: WHO, 2013. http://www.who.int/tb/publications/global_report/en (accessed Nov 2013).
3. Department of Foreign Affairs and Trade. East Asia leaders agree to collective action on malaria. Canberra: Australian Government, 2012. http://aid.dfat.gov.au/LatestNews/Pages/East-Asia-leaders-agree-to-collective-action-on-malaria.aspx (accessed Nov 2013).
4. World Health Assembly. Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis (WHA 62.15). Geneva: World Health Organization, 2009. http://www.who.int/tb/features_archive/wha62_15_tb_resolution/en/index.html (accessed Sep 2013).
5. Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004; 10: 1117-1121.
6. Marais BJ, Mlambo CK, Rastogi N, et al. Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol 2013; 51: 1818-1825.
7. International Civil Society Support. Cost of inaction: a report on how inadequate investment in the Global Fund to Fight AIDS, Tuberculosis and Malaria will affect millions of lives. Amsterdam: ICSS, 2013. http://icssupport.org/wp-content/uploads/2010/04/COST-OF-INACTION-Sep-12th-2013.pdf (accessed Sep 2013).
8. Lumb R, Bastian I, Carter R, et al. Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2010. A report of the Australian Mycobacterium Reference Laboratory Network. Commun Dis Intell Q Rep 2013; 37: E40-E46.
9. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63-80.
10. Wu J, Dalal K. Tuberculosis in Asia and the Pacific: the role of socioeconomic status and health system development. Int J Prev Med 2012; 3: 8-16.

Online responses are no longer available. Please refer to our instructions for authors page for more information.